Brainstem Glioma Prognosis and Surgical Management

Brainstem gliomas encompass a spectrum of primary central nervous system tumours arising within the midbrain, pons and medulla. Their prognosis varies from indolent low-grade lesions amenable to surgical excision, to highly aggressive diffuse intrinsic pontine gliomas with a median survival of less than one year. Critical determinants of outcome include patient age, performance status, molecular subclassification and extent of resection. Surgical management poses unique challenges owing to the density of vital neural pathways; nevertheless, advances in microsurgical techniques, intraoperative neurophysiological monitoring and high-resolution tractography have expanded the role of resection in carefully selected cases. Gross total resection confers a survival advantage in low-grade and some focal high-grade tumours, while stereotactic biopsy often remains the primary means of histological and molecular diagnosis in diffuse disease. Radiotherapy and chemotherapy serve as key adjuvant modalities, yet their benefit is tempered by the risk of radiation-induced neurotoxicity and the relative chemoresistance of many brainstem glioma subtypes. A deeper understanding of tumour biology, informed by integrated genomic and epigenomic profiling, is reshaping classification systems and guiding personalised therapeutic strategies.

Research from Nature Portfolio

A comprehensive genomic and epigenomic study has delineated distinct molecular clusters within brainstem gliomas, termed H3-Pons, H3-Medulla, IDH and PA-like, each defined by unique DNA methylation signatures and mutational landscapes. These clusters correlate strongly with anatomical site, histone H3 mutation status and clinical outcome, revealing divergent oncogenic pathways across the brainstem. Patients within the H3-Pons and H3-Medulla groups, both characterised by H3F3A alterations, exhibit significantly poorer survival compared with IDH-mutant and PA-like cases. This integrated classification enhances prognostic precision and lays the groundwork for targeted therapeutic development by linking molecular subtype to tumour location and patient prognosis.

Brainstem Glioma Prognosis and Surgical Management publication trend

The graph below shows the total number of articles in brainstem glioma prognosis and surgical management across all publications each year (not limited to Nature Index journals).

Technical terms

Brainstem glioma: A glial tumour located in the midbrain, pons or medulla with variable histological grade and clinical behaviour.

Gross total resection (GTR): Surgical removal of all visible tumour, as determined by intraoperative assessment and postoperative imaging.

Subtotal resection (STR): Surgical removal of most but not all detectable tumour, often employed when complete excision risks significant neurological deficit.

Diffuse intrinsic pontine glioma (DIPG): A particularly aggressive subset of brainstem glioma arising in the pons, typically harbouring histone H3 K27M mutations.

Tumour microenvironment (TME): The non-neoplastic cellular and extracellular components surrounding cancer cells, influencing growth, invasion and therapeutic response.

DNA methylation: An epigenetic modification involving methyl groups added to cytosine residues, used to classify gliomas into molecular subtypes.

Radiomics: The extraction of quantitative features from medical images to inform diagnosis, prognosis and treatment planning.

References

1. Surgical Management of Adult Brainstem Gliomas: A Systematic Review and Meta-Analysis. Current Oncology (2023).
2. The integrated genomic and epigenomic landscape of brainstem glioma. Nature Communications (2020).
3. Classification of Brainstem Gliomas Based on Tumor Microenvironment Status. Cancers (2023).
4. The Survival Benefits of Surgical Resection and Adjuvant Therapy for Patients With Brainstem Glioma. Frontiers in Oncology (2021).